INTERNATIONAL CONGRESS OF
PharmacoGenetics
Meta-analysis of breast cancer and association with phenotypes of common polymorphisms in Iran
-
Majid Mesgartehrani,1,* Negar Nilforoush,2 Mohammad Mahdi Eslami,3 Saeid Mirlohi,4
1. Iran Genomics Scientific Pole, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. The International Biotech School
3. Tehran University of Medical Sciences, Tehran, Iran
4. Tehran University of Medical Sciences, Tehran, Iran
- Introduction: Breast cancer is a critical global public health issue and the most frequently diagnosed cancer worldwide. From January to June 2023, the World Health Organization (WHO) recorded 577 new cancer cases, including 33 breast cancer cases.
- Methods: Common polymorphisms were selected based on citation and population data from the National Center for Biotechnology Information (NCBI). In addition, we evaluated related drug treatments in Iran and analyzed their related side effects. Data were then processed using MagaGene software, a specialized pharmacogenetic tool.
- Results: Our analysis revealed prevalent phenotypes associated with breast cancer. We also identified which specific phenotypes are likely to appear when cancer develops. Furthermore, we identified which side effects of drugs available in Iran might have a genetic basis.
- Conclusion: We recommend that oncologists conduct Sanger sequencing to ascertain the genetic profiles of breast cancer patients. This approach enables the selection of alternative therapies with potentially reduced side effects based on the patient's genetic makeup.
- Keywords: Breast cancer, pharmacogenetics, polymorphisms, drug side effects, Sanger sequencing.
